Eaton delivered beats on the top and bottom lines on Tuesday but saw its stock slip as investors took profits after a 30% gain so far this year. We see a buying opportunity. Revenue increased 8% year over year organically to a new first-quarter record of $5.94 billion, outpacing analyst …
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in …
The major U.S. stock indexes closed higher for the week, with the S & P 500 and Nasdaq Composite breaking multiweek losing streaks. Earnings drove the action, despite some less-than-ideal macroeconomic reports on economic growth and inflation. Meta Platforms ‘ report gave the market a bit of a scare Wednesday …
Microsoft delivered picture-perfect earnings after the bell Thursday, calming the market’s brief fears about runaway spending on AI infrastructure without the cloud revenues to show for it. Revenue increased about 17% year over year, to $61.86 billion, beating the Street consensus estimate of $60.8 billion, according to data from LSEG. …
Ford Motor on Wednesday evening delivered higher than expected profits in the first quarter, driven by strength in its commercial business. Positive updates to its full-year outlook helped send shares rallying by roughly 2.5% in after-hours trading. Automotive revenue increased 2% year over year, to $38.89 billion, missing analysts’ forecasts …
It was another ugly week for stocks. The S & P 500 and the Nasdaq on Friday extended their declines to six straight sessions, their worst losing streaks in more than 1½ years. The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering …
Abbott Laboratories delivered a top and bottom line beat Wednesday and surprised investors by raising its full-year guidance — a show of confidence by the medical device maker not seen in a first quarter since 2016. Revenue for the three months ended March 31 rose slightly more than 2% year …
We’ve become prisoners of short-rate forecasts. Yeah, the ones controlled by the Federal Reserve. But those fearless investors who have broken out of this self-imposed mental jail are enjoying bountiful returns. Sure, it appears to be nothing but alchemy to the jailers and their powerful protagonists in the media. But …
CNBC’s Jim Cramer on Thursday guided investors through next week’s Wall Street action, saying to pay attention to new nonfarm payroll data and Walt Disney’s annual shareholder meeting, where its long and arduous proxy fight will come to a head. “In my view, the market’s now well-prepared for a hot employment …
Shortly after the opening bell, we will be buying 140 shares of Abbott Laboratories at roughly $112. Following the trade, Jim Cramer’s Charitable Trust will own 700 shares of ABT, increasing our weighting in the portfolio to 2.42% from 1.95%. We are buying more Abbott Laboratories into its recent weakness …